Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Receivables (2018 - 2023)

Endonovo Therapeutics has reported Receivables over the past 8 years, most recently at $3370.0 for Q1 2023.

  • Quarterly results put Receivables at $3370.0 for Q1 2023, up 256.61% from a year ago — trailing twelve months through Mar 2023 was $3370.0 (up 256.61% YoY), and the annual figure for FY2021 was $944.0, changed 0.21%.
  • Receivables for Q1 2023 was $3370.0 at Endonovo Therapeutics, up from $944.0 in the prior quarter.
  • Over the last five years, Receivables for ENDV hit a ceiling of $22742.0 in Q4 2019 and a floor of $941.0 in Q2 2020.
  • Median Receivables over the past 5 years was $3226.0 (2020), compared with a mean of $5612.5.
  • Biggest five-year swings in Receivables: plummeted 95.86% in 2020 and later surged 900.74% in 2021.
  • Endonovo Therapeutics' Receivables stood at $22742.0 in 2019, then plummeted by 95.86% to $942.0 in 2020, then grew by 0.21% to $944.0 in 2021, then changed by 0.0% to $944.0 in 2022, then skyrocketed by 256.99% to $3370.0 in 2023.
  • The last three reported values for Receivables were $3370.0 (Q1 2023), $944.0 (Q3 2022), and $945.0 (Q2 2022) per Business Quant data.